DB:RFS

Stock Analysis Report

Executive Summary

Resverlogix Corp. operates as a late-stage clinical biotechnology company.

Snowflake

Fundamentals

Weak fundamentals or lack of information.

Share Price & News

How has Resverlogix's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: RFS's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-27.2%

RFS

5.5%

DE Biotechs

-0.3%

DE Market


1 Year Return

-59.0%

RFS

-1.9%

DE Biotechs

10.9%

DE Market

Return vs Industry: RFS underperformed the German Biotechs industry which returned -1.9% over the past year.

Return vs Market: RFS underperformed the German Market which returned 10.9% over the past year.


Shareholder returns

RFSIndustryMarket
7 Day-27.2%5.5%-0.3%
30 Day-8.6%-0.8%2.6%
90 Day-56.6%-4.8%11.8%
1 Year-59.0%-59.0%-1.6%-1.9%14.4%10.9%
3 Year-31.7%-31.7%65.5%63.4%24.1%13.2%
5 Year126.5%126.5%7.2%4.8%33.0%14.8%

Price Volatility Vs. Market

How volatile is Resverlogix's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Resverlogix undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Resverlogix is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Resverlogix has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Resverlogix forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

50.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Resverlogix has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Resverlogix performed over the past 5 years?

-52.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: RFS has large one-off items impacting its financial results.

Growing Profit Margin: RFS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: RFS is unprofitable, and losses have increased over the past 5 years at a rate of -52.1% per year.

Accelerating Growth: Unable to compare RFS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RFS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: RFS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Resverlogix's financial position?


Financial Position Analysis

Short Term Liabilities: RFS has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: RFS has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: RFS has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: RFS's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: RFS has a low level of unsold assets or inventory.

Debt Coverage by Assets: RFS has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: RFS has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: RFS has less than a year of cash runway if free cash flow continues to reduce at historical rates of -26.6% each year


Next Steps

Dividend

What is Resverlogix's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate RFS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate RFS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RFS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RFS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RFS's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of Resverlogix's salary, the management and board of directors tenure and is there insider trading?

12.5yrs

Average management tenure


CEO

Don McCaffrey 0

16.6yrs

Tenure

US$1,954,165

Compensation

Mr. Donald J. McCaffrey, also known as Don, is a Co-Founder of Resverlogix Corporation and has been its Chief Executive Officer, President since April 25, 2003 and has also been its Chairman of the Board s ...


CEO Compensation Analysis

Compensation vs Market: Don's total compensation ($USD1.47M) is above average for companies of similar size in the German market ($USD513.69K).

Compensation vs Earnings: Don's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

12.5yrs

Average Tenure

Experienced Management: RFS's management team is seasoned and experienced (12.5 years average tenure).


Board Age and Tenure

7.3yrs

Average Tenure

70yo

Average Age

Experienced Board: RFS's board of directors are considered experienced (7.3 years average tenure).


Insider Trading

Insider Buying: RFS insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$48,81228 Aug 19
Jan Johansson
EntityIndividual
Role
Senior Key Executive
Senior Vice President of Medical Affairs
Shares25,000
Max PriceUS$1.97
SellUS$23,82611 Jul 19
Jan Johansson
EntityIndividual
Role
Senior Key Executive
Senior Vice President of Medical Affairs
Shares11,800
Max PriceUS$2.02
BuyUS$8,959,18301 Apr 19
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
EntityCompany
Shares4,479,793
Max PriceUS$2.00
BuyUS$4,409,55531 Jan 19
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
EntityCompany
Shares2,213,398
Max PriceUS$1.99

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 25.5%.


Management Team

  • Jan Johansson

    Senior Vice President of Medical Affairs

    • Tenure: 15.7yrs
    • Compensation: US$306.46k
  • Don McCaffrey

    Co-Founder

    • Tenure: 16.6yrs
    • Compensation: US$1.95m
  • Norman C. Wong

    Co-Founder

    • Tenure: 6.6yrs
  • Paul Moon

    Vice President of Investor Relations & Communications

    • Tenure: 0yrs
  • Ken Lebioda

    Senior Vice President of Business & Corporate Development

    • Tenure: 14.8yrs
    • Compensation: US$693.46k
  • Brad Cann

    Chief Financial Officer

    • Tenure: 10.1yrs
    • Compensation: US$745.34k
  • Mike Sweeney (58yo)

    Senior Vice President of Clinical Development

    • Tenure: 5yrs
    • Compensation: US$1.37m
  • Sarah Zapotichny

    Director of Investor Relations & Corporate Communications

    • Tenure: 0yrs
  • Ewelina Kulikowski

    Senior Vice President of Research & Development

    • Tenure: 3.6yrs
    • Compensation: US$635.03k

Board Members

  • Ken Zuerblis (60yo)

    Independent Director

    • Tenure: 9.2yrs
    • Compensation: US$359.79k
  • Eldon Smith (79yo)

    Lead Director

    • Tenure: 3.6yrs
    • Compensation: US$447.58k
  • Don McCaffrey

    Co-Founder

    • Tenure: 16.6yrs
    • Compensation: US$1.95m
  • Norman C. Wong

    Co-Founder

    • Tenure: 6.6yrs
  • Jeff Cummings (70yo)

    Member of Neurodegenerative Clinical & Scientific Advisory Board

    • Tenure: 7.3yrs
  • Kelly McNeill

    Independent Director

    • Tenure: 10.1yrs
    • Compensation: US$355.41k
  • Bengt Winblad

    Chairman of Neurodegenerative Clinical & Scientific Advisory Board

    • Tenure: 7.3yrs
  • Henrik Zetterberg

    Member of Neurodegenerative Clinical & Scientific Advisory Board

    • Tenure: 7.3yrs
  • Rada Koldamova

    Member of Neurodegenerative Clinical & Scientific Advisory Board

    • Tenure: 7.3yrs
  • Kam Kalantar-Zadeh

    Chairman of Renal Clinical Advisory Board

    • Tenure: 0yrs

Company Information

Resverlogix Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Resverlogix Corp.
  • Ticker: RFS
  • Exchange: DB
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$265.963m
  • Listing Market Cap: CA$181.394m
  • Shares outstanding: 209.42m
  • Website: https://www.resverlogix.com

Number of Employees


Location

  • Resverlogix Corp.
  • 4820 Richard Road SW
  • Suite 300
  • Calgary
  • Alberta
  • T3E 6L1
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RVXTSX (The Toronto Stock Exchange)YesCommon SharesCACADApr 2003
RFSDB (Deutsche Boerse AG)YesCommon SharesDEEURApr 2003
RVXC.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDApr 2003
0VF9LSE (London Stock Exchange)YesCommon SharesGBCADApr 2003

Biography

Resverlogix Corp. operates as a late-stage clinical biotechnology company. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III c ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/22 21:26
End of Day Share Price2019/11/22 00:00
Earnings2019/07/31
Annual Earnings2019/04/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.